Hereditary Angioedema Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Hereditary Angioedema Treatment Market

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling (edema) in various parts of the body, including the throat, face, hands, and feet. These episodes can be life-threatening, particularly when they involve the airways. The global market for HAE treatments has been experiencing significant growth, driven by increased awareness, advancements in diagnostic techniques, and the development of novel therapies.

Market Overview

In 2017, the global hereditary angioedema treatment market was valued at approximately USD 1,883.1 million. Projections indicate that this market is expected treach USD 17,312.1 million by the end of 2032, exhibiting a compound annual growth rate (CAGR) of 16.5% during the forecast period from 2017 t2032.

Key Drivers of Market Growth

1. Increasing Prevalence and Diagnosis: Advancements in diagnostic technologies have facilitated earlier and more accurate detection of HAE. This has led ta rise in diagnosed cases, thereby increasing the demand for effective treatment options.

2. Advancements in Treatment Options: The development and approval of new therapies have expanded the arsenal of treatments available tHAE patients. For instance, in August 2018, Shire (now part of Takeda Pharmaceutical Company) announced the U.S. Food and Drug Administration (FDA) approval of TAKHZYRO (lanadelumab-flyo) for prophylactic treatment of HAE in patients aged 12 years and older.

3. Rising Awareness and Preventive Care: There is a growing emphasis on preventive care in managing HAE. Prophylactic treatments are gaining traction as they help in reducing the frequency and severity of HAE attacks, improving the quality of life for patients.

Dominant Drug Class: C-1 Esterase Inhibitors

Among the various drug classes used in HAE treatment, C-1 esterase inhibitors have emerged as the most prominent. In 2017, this segment accounted for approximately 61.3% of the total market share. C-1 esterase inhibitors work by replacing the deficient or dysfunctional C1-inhibitor protein in patients, thereby preventing the cascade of events leading tangioedema attacks.

Application Segments: Prophylaxis vs. Treatment

The HAE treatment market is segmented intprophylaxis (preventive treatment) and on-demand (acute) treatment. The prophylaxis segment is anticipated tbe the fastest-growing during the forecast period. This growth is attributed tthe sustained demand and increasing adoption of preventive therapies, especially in developed nations, aiming treduce the frequency of HAE attacks and improve patient outcomes.

Regional Insights

North America held a significant share of the HAE treatment market in 2017, with a valuation of approximately USD 1,752.2 million. This dominance is expected tcontinue, driven by factors such as a well-established healthcare infrastructure, higher awareness levels, and the availability of advanced treatment options. Europe is anticipated thold the second-largest market share, supported by high healthcare expenditure and access tadvanced diagnostics.

Competitive Landscape

The HAE treatment market is consolidated, with key players including CSL Behring, Shire (now part of Takeda Pharmaceutical Company), and Pharming Group NV. These companies collectively accounted for a significant portion of the market share in 2017. Their strong market positions are attributed testablished brand value, competitive pricing strategies, and robust distribution networks.

Future Outlook

The hereditary angioedema treatment market is poised for substantial growth in the coming years. Ongoing research and development efforts are focused on introducing innovative therapies, including gene therapies and novel biologics, aiming tprovide more effective and convenient treatment options for patients. Additionally, increasing awareness campaigns and patient support programs are expected tenhance diagnosis rates and treatment adoption globally.

Conclusion

Hereditary angioedema, though rare, poses significant health challenges due tits unpredictable and potentially life-threatening nature. The expanding treatment landscape, characterized by the introduction of new therapies and a focus on preventive care, offers hope for improved patient outcomes. As the market continues tgrow, collaborations between pharmaceutical companies, healthcare providers, and patient advocacy groups will be crucial in addressing unmet clinical needs and ensuring access teffective treatments worldwide.

SEGMENTATION DETAILS

By Drug Class

• C-1 Esterase Inhibitors
• Bradykynin Receptor Antagonist
• Kallikrein Inhibitors

By Application

• Prophylaxis
• Treatment

By Route of Administration

• IV
• Subcutaneous

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

By Geography

• North America (USA and Canada)
• Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
• Rest of the World

Please Note: It will take 5-6 business days to complete the report upon order confirmation.